Loading...
Loading...
SGTX| Name | Value |
|---|---|
| Revenues | 5.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 5.9M |
| Operating Expense | 13.3M |
| Operating I/L | -7.4M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.4M |
| Pretax | -7.5M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -7.5M |
Sigilon Therapeutics, Inc. is a clinical stage biotechnology company focused on developing functional cures for chronic diseases. Its lead product candidate, SIG-001, is in Phase I/II clinical trial for Hemophilia A. The company is also developing SIG-005 for mucopolysaccharidosis type 1, SIG-007 for Fabry disease, and SIG-002 for type 1 diabetes. Sigilon has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for type 1 diabetes treatment.
